Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Autoimmune Disorders

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 286 articles:
HTML format



Single Articles


    July 2022
  1. MURAKAMI K, Miyamoto K, Terayama A, Yoshikawa K, et al
    Acute eye movement-retained internal ophthalmoplegia in atypical Miller Fisher syndrome variants are associated with IgG anti-GQ1b antibodies.
    J Neuroimmunol. 2022;368:577880.
    PubMed     Abstract available


  2. DAS NEVES SP, Serre-Miranda C, Sousa JC, Costa PS, et al
    Lipocalin-2 does not influence EAE clinical score but it increases inflammation in central nervous system.
    J Neuroimmunol. 2022;368:577872.
    PubMed     Abstract available


    June 2022
  3. RACKE MK, Niles JK, Lorenz RA, Kaufman HW, et al
    Changes in ganglioside antibody positivity rates during the COVID-19 pandemic.
    J Neuroimmunol. 2022;367:577877.
    PubMed     Abstract available


  4. NIE DA, Abud A, Serrano-Gonzalez M, Harappanahally G, et al
    Pediatric stiff limb syndrome with polyautoimmunity of anti-GAD-65, anti-islet cell, and thyroid peroxidase antibodies: A case report and review of literature.
    J Neuroimmunol. 2022;367:577865.
    PubMed     Abstract available


  5. MASI G, Li Y, Karatz T, Pham MC, et al
    The clinical need for clustered AChR cell-based assay testing of seronegative MG.
    J Neuroimmunol. 2022;367:577850.
    PubMed     Abstract available


  6. HU K, Yang Y, Liu J, Chen X, et al
    Susac syndrome with the typical clinical triad: A case report and literature review.
    J Neuroimmunol. 2022;367:577822.
    PubMed     Abstract available


  7. YAO Y, Zhang O, Gu L, Zhang X, et al
    Analysis of risk factors for a poor functional prognosis and relapse in patients with autoimmune encephalitis.
    J Neuroimmunol. 2022;369:577899.
    PubMed     Abstract available


  8. CHAN F, Riminton DS, Ramanathan S, Reddel SW, et al
    Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to "overlap" cases.
    J Neuroimmunol. 2022;369:577904.
    PubMed     Abstract available


    May 2022
  9. YAO Y, Uddin MN, Manley K, Lawrence DA, et al
    Improvements of autism-like behaviors but limited effects on immune cell metabolism after mitochondrial replacement in BTBR T(+)Itpr3(tf)/J mice.
    J Neuroimmunol. 2022;368:577893.
    PubMed     Abstract available


  10. KLEIN CJ, Beecher G, Lamb C, Naddaf E, et al
    LRP4-IgG service line testing in seronegative myasthenia gravis and controls.
    J Neuroimmunol. 2022;368:577895.
    PubMed     Abstract available


  11. PAUL SA, Roy D, Mondal GP, Bhattacharyya R, et al
    Primary angiitis of central nervous system - A challenging diagnosis.
    J Neuroimmunol. 2022;366:577844.
    PubMed     Abstract available


  12. DINOTO A, McKeon A, Vattemi G, Carta S, et al
    Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma.
    J Neuroimmunol. 2022;368:577882.
    PubMed     Abstract available


  13. GILL AJ, Venkatesan A
    Pathogenic mechanisms in neuronal surface autoantibody-mediated encephalitis.
    J Neuroimmunol. 2022;368:577867.
    PubMed     Abstract available


    April 2022
  14. WANG J, Jin L, Zhang X, Yu H, et al
    Activated microglia by (18)F-DPA714 PET in a case of anti-LGI1 autoimmune encephalitis.
    J Neuroimmunol. 2022;368:577879.
    PubMed     Abstract available


  15. FERILLI MAN, Papi C, Sabatelli M, Colosimo C, et al
    MOG autoimmunity mimicking CLIPPERS syndrome: Case report and literature review.
    J Neuroimmunol. 2022;367:577875.
    PubMed     Abstract available


  16. MA R, Chu Y, Dou M, Jing Y, et al
    Matrine inhibits the Wnt3a/beta-catenin/TCF7L2 signaling pathway in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;367:577876.
    PubMed     Abstract available


  17. KYLLESBECH C, Trier N, Slibinskas R, Ciplys E, et al
    Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.
    J Neuroimmunol. 2022;367:577868.
    PubMed     Abstract available


  18. ODA F, Uzawa A, Ozawa Y, Yasuda M, et al
    Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy.
    J Neuroimmunol. 2022;365:577833.
    PubMed     Abstract available


  19. DEKEYSER C, Naesens L, Offner F, De Vriendt C, et al
    A unique phenotype of longitudinal extensive transverse myelitis in autoimmune lymphoproliferative syndrome.
    J Neuroimmunol. 2022;367:577866.
    PubMed     Abstract available


  20. MCKEON-MAKKI I, McKeon A, Yang B, Pittock SJ, et al
    Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients.
    J Neuroimmunol. 2022;367:577861.
    PubMed     Abstract available


    March 2022
  21. JIN J, Shneyderman M, Smith MD, Gharagozloo M, et al
    Retinal pathology in spontaneous opticospinal experimental autoimmune encephalitis mice.
    J Neuroimmunol. 2022;367:577859.
    PubMed     Abstract available


  22. TOTTENHAM I, Koch M, Camara-Lemarroy C
    Serum HGF and APN2 are associated with disability worsening in SPMS.
    J Neuroimmunol. 2022;364:577803.
    PubMed     Abstract available


  23. NEPAL G, Kharel S, Coghlan MA, Rayamajhi P, et al
    Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
    J Neuroimmunol. 2022;364:577812.
    PubMed     Abstract available


  24. WENG J, Du Z, Zhang Y
    CNS limited ANCA-associated vasculitis presenting as an isolated intraparenchymal mass.
    J Neuroimmunol. 2022;364:577791.
    PubMed     Abstract available


  25. DIAZ P, Leveque M, Hautecloque G, Sellal F, et al
    The challenge of diagnosing Guillain-Barre syndrome in patients with COVID-19 in the intensive care unit.
    J Neuroimmunol. 2022;366:577842.
    PubMed     Abstract available


  26. SALARI AA, Jand Y, Ghazi-Khansari M
    Antibiotic treatment during pregnancy and lactation in dams exacerbates clinical symptoms and inflammatory responses in offspring with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;366:577840.
    PubMed     Abstract available


    February 2022
  27. MA J, Yu H, Wang H, Zhang X, et al
    Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    J Neuroimmunol. 2022;363:577790.
    PubMed     Abstract available


  28. COSTA D, Sardoeira A, Carneiro P, Neves E, et al
    Autoimmune encephalitis: suspicion in clinical practice and mimics.
    J Neuroimmunol. 2022;365:577824.
    PubMed     Abstract available


    January 2022
  29. MOLLER L, Kerwat M, Timmermann L, Simon OJ, et al
    When your cat takes you to the ICU: Miller Fisher/ Guillain-Barre-overlap-syndrome caused by Pasteurella multocida infection resembling wound botulism.
    J Neuroimmunol. 2022;365:577821.
    PubMed     Abstract available


  30. ISMAIL II, Salama S
    A systematic review of cases of CNS demyelination following COVID-19 vaccination.
    J Neuroimmunol. 2022;362:577765.
    PubMed     Abstract available


  31. MA X, Chen C, Fang L, Zhong X, et al
    Dysregulated CD40 and CD40 ligand expression in anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2022;362:577762.
    PubMed     Abstract available


  32. KADISH R, Clardy SL, Royston M, Tanvir I, et al
    Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis.
    J Neuroimmunol. 2022;362:577761.
    PubMed     Abstract available


  33. KALININ S, Boullerne AI, Feinstein DL
    Serum levels of lipocalin-2 are elevated at early times in African American relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2022;364:577810.
    PubMed     Abstract available


  34. YE F, Dai Y, Wang T, Liang J, et al
    Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2022;364:577809.
    PubMed     Abstract available


  35. BRORSON IS, Eriksson AM, Hogestol E, Leikfoss IS, et al
    Global DNA methylation changes in treated and untreated MS patients measured over time.
    J Neuroimmunol. 2022;364:577808.
    PubMed     Abstract available


  36. URRIOLA N, Blazek K, Adelstein S
    Subunit-specific autoantibodies in autoimmune autonomic ganglionopathy.
    J Neuroimmunol. 2022;363:577805.
    PubMed     Abstract available


    December 2021
  37. RONCHI NR, Silva GD
    Comparison of the clinical syndromes of anti-GABAa versus anti-GABAb associated autoimmune encephalitis: A systematic review.
    J Neuroimmunol. 2021;363:577804.
    PubMed     Abstract available


  38. DIAS DA COSTA M, Leal Rato M, Cruz D, Valadas A, et al
    Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection.
    J Neuroimmunol. 2021;361:577739.
    PubMed     Abstract available


  39. THOLANCE Y, Antoine JC, Mohr L, Jung M, et al
    Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy pattern.
    J Neuroimmunol. 2021;361:577757.
    PubMed     Abstract available


  40. TALBOT J, Hojsgaard Chow H, Holm Hansen R, von Essen MR, et al
    Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
    J Neuroimmunol. 2021;361:577756.
    PubMed     Abstract available


  41. REN H, Fan S, Zhao Y, Guan H, et al
    The changing spectrum of antibody-mediated encephalitis in China.
    J Neuroimmunol. 2021;361:577753.
    PubMed     Abstract available


  42. PUJARI SS, Kulkarni RV, Ojha P, Gursahani R, et al
    Acute haemorrhagic leukoencephalitis (AHLE) - our experience and a short review.
    J Neuroimmunol. 2021;361:577751.
    PubMed     Abstract available


  43. DIAS L, Barbosa L, Martins F, Braz L, et al
    Risk factors for idiopathic myelitis at admission and predictors for late diagnostic change.
    J Neuroimmunol. 2021;361:577747.
    PubMed     Abstract available


  44. SAHA S, Mukherjee S, Guha G, Mukhopadhyay D, et al
    Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study.
    J Neuroimmunol. 2021;361:577752.
    PubMed     Abstract available


  45. NAGIREDDY RBR, Kumar A, Singh VK, Prasad R, et al
    Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    J Neuroimmunol. 2021;361:577742.
    PubMed     Abstract available


  46. KESHVARI MK, van Someren F, Sheikh S, Galea I, et al
    Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns.
    J Neuroimmunol. 2021;361:577729.
    PubMed     Abstract available


  47. STECK AJ
    Anti-MAG neuropathy: From biology to clinical management.
    J Neuroimmunol. 2021;361:577725.
    PubMed     Abstract available


  48. ADAMEC I, Rogic D, Penz MG, Braun C, et al
    Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
    J Neuroimmunol. 2021;362:577788.
    PubMed     Abstract available


  49. SONG J, Yang J, Jing S, Yan C, et al
    Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets.
    J Neuroimmunol. 2021;362:577787.
    PubMed     Abstract available


  50. TOLJAN K, Amin M, Kunchok A, Ontaneda D, et al
    New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.
    J Neuroimmunol. 2021;362:577785.
    PubMed     Abstract available


    November 2021
  51. CHEN B, Tian DS, Bu BT
    Immunological predictors for the outcome in patients with antibody-mediated autoimmune encephalitis.
    J Neuroimmunol. 2021;362:577779.
    PubMed     Abstract available


  52. CARAVAGNA C
    Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.
    J Neuroimmunol. 2021;362:577780.
    PubMed    


  53. WUERCH E, Mishra M, Melo H, Ebacher V, et al
    Quantitative analysis of spinal cord neuropathology in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;362:577777.
    PubMed     Abstract available


  54. JIAO L, Li H, Guo S
    Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
    J Neuroimmunol. 2021;362:577767.
    PubMed     Abstract available


  55. HWANG D, Boehm A, Rostami A, Zhang GX, et al
    Oral D-mannose treatment suppresses experimental autoimmune encephalomyelitis via induction of regulatory T cells.
    J Neuroimmunol. 2021;362:577778.
    PubMed     Abstract available


  56. HASSANSHAHI G, Noroozi Karimabad M, Jebali A
    The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
    J Neuroimmunol. 2021;362:577768.
    PubMed     Abstract available


  57. FINSTERER J
    SARS-CoV-2 vaccinations may not only be complicated by GBS but also by distal small fibre neuropathy.
    J Neuroimmunol. 2021;360:577703.
    PubMed    


  58. POURMOGHADDAS Z, Sadeghizadeh A, Tara SZ, Zandifar A, et al
    Longitudinally extensive transverse myelitis as a sign of multisystem inflammatory syndrome following COVID-19 infection: A pediatric case report.
    J Neuroimmunol. 2021;360:577704.
    PubMed     Abstract available


  59. MOLAZADEH N, Filippatou AG, Vasileiou ES, Levy M, et al
    Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2021;360:577702.
    PubMed     Abstract available


  60. FREEDMAN MS, Wojcik J, Holmberg KH, Fluck M, et al
    Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
    J Neuroimmunol. 2021;360:577715.
    PubMed     Abstract available


  61. NILLES C, Poillon G, Deschamps L, Daval M, et al
    IgG4-related pachymeningitis and mastoiditis, associated with cerebral venous thrombosis: A case report.
    J Neuroimmunol. 2021;360:577717.
    PubMed     Abstract available


  62. PANDIT L, Malli C, D'Cunha A, Sudhir A, et al
    Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay.
    J Neuroimmunol. 2021;360:577706.
    PubMed     Abstract available


  63. PACHE F, Ringelstein M, Aktas O, Kleiter I, et al
    C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    J Neuroimmunol. 2021;360:577699.
    PubMed     Abstract available


  64. MASCIA E, Clarelli F, Zauli A, Guaschino C, et al
    Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.
    J Neuroimmunol. 2021;362:577760.
    PubMed     Abstract available


    October 2021
  65. VAKRAKOU AG, Tzanetakos D, Evangelopoulos ME, Fragoulis GE, et al
    IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;361:577759.
    PubMed     Abstract available


  66. FUJIMORI J, Miyazawa K, Nakashima I
    Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neuroimmunol. 2021;361:577755.
    PubMed     Abstract available


  67. ZELADA-RIOS L, Pacheco-Barrios K, Galecio-Castillo M, Yamunaque-Chunga C, et al
    Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases.
    J Neuroimmunol. 2021;359:577674.
    PubMed     Abstract available


  68. SRIWASTAVA S, Lisak RP
    Acetylcholine receptor antibodies in a patient with sensory neuropathy.
    J Neuroimmunol. 2021;359:577692.
    PubMed     Abstract available


  69. TANG H, Wang L, Zhou H, Hao X, et al
    Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases.
    J Neuroimmunol. 2021;359:577693.
    PubMed     Abstract available


  70. GOI LDS, Altenhofen S, Nabinger DD, Bonan CD, et al
    Decreased convulsive threshold and memory loss after anti-NMDAR positive CSF injection in zebrafish.
    J Neuroimmunol. 2021;359:577689.
    PubMed     Abstract available


  71. OTA S, Kotani T, Matsuda S, Nishioka D, et al
    Initial serum GM-CSF levels are associated with the severity of cerebral small vessel disease in microscopic polyangiitis patients.
    J Neuroimmunol. 2021;359:577671.
    PubMed     Abstract available


  72. SANTIAGO JA, Babico M, Stitt G, Thomas CA, et al
    Low-dose intrathecal rituximab is a safe and potentially effective treatment for pediatric neuroimmunologic disorders.
    J Neuroimmunol. 2021;359:577687.
    PubMed     Abstract available


  73. ACHIRON A, Mandel M, Dreyer-Alster S, Harari G, et al
    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
    J Neuroimmunol. 2021;361:577746.
    PubMed     Abstract available


  74. KIMURA A, Kato S, Takekoshi A, Yoshikura N, et al
    Autoimmune glial fibrillary acidic protein astrocytopathy resembling isolated central nervous system lymphomatoid granulomatosis.
    J Neuroimmunol. 2021;361:577748.
    PubMed     Abstract available


  75. CHE NN, Chen SY, Li X, Ma JJ, et al
    Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
    J Neuroimmunol. 2021;361:577738.
    PubMed     Abstract available


  76. SEGAL JP, Phillips S, Dubois RM, Silva JR, et al
    Weight bearing as a measure of disease progression in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;361:577730.
    PubMed     Abstract available


    September 2021
  77. OO WM, Giri P, de Souza A
    AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link?
    J Neuroimmunol. 2021;360:577719.
    PubMed     Abstract available


  78. SAMUDRALWAR RD
    Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.
    J Neuroimmunol. 2021;358:577660.
    PubMed    


  79. GHOSH R, Dubey S, Mandal A, Ray BK, et al
    Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.
    J Neuroimmunol. 2021;358:577655.
    PubMed     Abstract available


  80. PAGENKOPF C, Sudmeyer M
    A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.
    J Neuroimmunol. 2021;358:577606.
    PubMed     Abstract available


  81. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed     Abstract available


  82. VAN LIEVERLOO GGA, Wieske L, van Schaik IN, Deijs M, et al
    Virus discovery in chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2021;358:577668.
    PubMed     Abstract available


  83. MORCH MT, Khorooshi R, Marczynska J, Dubik M, et al
    Mitochondria-A target for attenuation of astrocyte pathology.
    J Neuroimmunol. 2021;358:577657.
    PubMed     Abstract available


  84. SECHI E, Zarbo R, Biancu MA, Chessa P, et al
    Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2021;358:577666.
    PubMed     Abstract available


  85. ZHAO X, Yang P
    Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies.
    J Neuroimmunol. 2021;358:577648.
    PubMed     Abstract available


  86. BAEK SH, Kim B, Shin JY, Choi SJ, et al
    EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines.
    J Neuroimmunol. 2021;358:577637.
    PubMed     Abstract available


  87. GOMBOLAY GY, Gadde JA
    Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review.
    J Neuroimmunol. 2021;358:577653.
    PubMed     Abstract available


  88. XIAO J, Chen X, Shang K, Tang Y, et al
    Clinical, neuroradiological, diagnostic and prognostic profile of autoimmune glial fibrillary acidic protein astrocytopathy: A pooled analysis of 324 cases from published data and a single-center retrospective study.
    J Neuroimmunol. 2021;360:577718.
    PubMed     Abstract available


  89. PHILLIPS O, Tubre T, Lorenco H, Batish SD, et al
    Limbic encephalitis in a child with ovarian teratoma and influenza B. Case report and critical review of the history of autoimmune anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2021;360:577716.
    PubMed     Abstract available


    August 2021
  90. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    PubMed     Abstract available


  91. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    PubMed     Abstract available


  92. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed     Abstract available


  93. BRAINER-LIMA JPM, Leite BHS, de Araujo CMCS, Dhalia R, et al
    Are Zika virus cross-reactive antibodies against aquaporin-4 associated to Neuromyelitis Optica Spectrum Disorder?
    J Neuroimmunol. 2021;360:577697.
    PubMed     Abstract available


  94. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed     Abstract available


  95. QIAO X, Wang H, Lu L, Chen J, et al
    Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice.
    J Neuroimmunol. 2021;357:577620.
    PubMed     Abstract available


  96. CHAKRABORTY AP, Pandit A, Ray BK, Mukherjee A, et al
    Capgras syndrome and confabulation unfurling anti NMDAR encephalitis with classical papillary thyroid carcinoma: First reported case.
    J Neuroimmunol. 2021;357:577611.
    PubMed     Abstract available


  97. EQUIZA J, Rodriguez-Antiguedad J, Campo-Caballero D, Iruzubieta P, et al
    Autoimmune GFAP astrocytopathy presenting with remarkable CNS hyperexcitability and oculogyric crises.
    J Neuroimmunol. 2021;359:577695.
    PubMed     Abstract available


  98. COSSU D, Yokoyama K, Sato S, Noda S, et al
    PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2021;359:577694.
    PubMed     Abstract available


  99. MIN YG, Ju W, Ha YE, Ban JJ, et al
    Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    J Neuroimmunol. 2021;359:577691.
    PubMed     Abstract available


  100. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    PubMed     Abstract available


    July 2021
  101. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    PubMed     Abstract available


  102. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    PubMed     Abstract available


  103. LAI QL, Cai MT, Zheng Y, Zhang TY, et al
    Seasonal variation in autoimmune encephalitis: A multi-center retrospective study.
    J Neuroimmunol. 2021;359:577673.
    PubMed     Abstract available


  104. YAO Y, Li X, Lin J, Zhang X, et al
    Thymoma-associated autoimmune encephalitis with positive Titin antibodies: A case report.
    J Neuroimmunol. 2021;358:577670.
    PubMed     Abstract available


  105. GUO L, Ren H, Fan S, Guan H, et al
    Autoantibody against the Rab6A/Rab6B in primary autoimmune cerebellar ataxia associated with Sjogren's syndrome: A case report.
    J Neuroimmunol. 2021;359:577667.
    PubMed     Abstract available


  106. WANG J, Yan C, Zhao Z, Chen H, et al
    Sexual dysfunction in patients with myasthenia gravis.
    J Neuroimmunol. 2021;358:577669.
    PubMed     Abstract available


  107. CAPARO-ZAMALLOA C, Alvarez-Toledo K, Yamunaque-Chunga C, Castro-Suarez S, et al
    Autoimmune neurology: Co-occurrence of anti-NMDAR encephalitis and anti-MOG associated disease, report of a case.
    J Neuroimmunol. 2021;358:577663.
    PubMed     Abstract available


  108. LOCKHART A, Boers P
    Paraneoplastic neurologic syndromes with multiple neural autoantibodies: A report of two cases.
    J Neuroimmunol. 2021;358:577665.
    PubMed     Abstract available


  109. LI R, Wang J, Li C, Liu X, et al
    Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.
    J Neuroimmunol. 2021;356:577604.
    PubMed     Abstract available


  110. DINOTO A, Cheli M, Bratina A, Sartori A, et al
    Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
    J Neuroimmunol. 2021;356:577586.
    PubMed     Abstract available


  111. NARESH K, Miraclin TA, Prabhakar AT, Mathew V, et al
    Epstein-Barr virus infection in a woman with aquaporin-4 seropositive neuromyelitis optica.
    J Neuroimmunol. 2021;356:577581.
    PubMed     Abstract available


  112. WONG CK, Hor JY, Loo YP, Heng HS, et al
    High incidence of NMDAR encephalitis among Austronesians: A population-based study in Sabah, Malaysia.
    J Neuroimmunol. 2021;356:577584.
    PubMed     Abstract available


  113. HONGO Y, Kaida K, Komuta Y, Takazaki H, et al
    Cholesterol-added antigens can enhance antiglycolipid antibody activity: Application to antibody testing.
    J Neuroimmunol. 2021;356:577580.
    PubMed     Abstract available


  114. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    PubMed     Abstract available


  115. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available


  116. CORTES-VICENTE E, Alvarez-Velasco R, Illa I, Gallardo E, et al
    Comment to "Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis".
    J Neuroimmunol. 2021;358:577659.
    PubMed    


  117. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available


  118. KHANMOHAMMADI S, Malekpour M, Jabbari P, Rezaei N, et al
    Genetic basis of Guillain-Barre syndrome.
    J Neuroimmunol. 2021;358:577651.
    PubMed     Abstract available


    June 2021
  119. MOSTAFA GA, Meguid NA, Shehab AAS, Elsaeid A, et al
    Plasma levels of nerve growth factor in Egyptian autistic children: Relation to hyperserotonemia and autoimmunity.
    J Neuroimmunol. 2021;358:577638.
    PubMed     Abstract available


  120. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    PubMed     Abstract available


  121. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available


  122. UZAWA A, Akamine H, Kojima Y, Ozawa Y, et al
    High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis.
    J Neuroimmunol. 2021;358:577634.
    PubMed     Abstract available


  123. FINSTERER J
    Steroid-responsive, transverse myelitis is a known complication of COVID-19.
    J Neuroimmunol. 2021;355:577566.
    PubMed    


  124. LEE JK, Kwon S, Han JH, Yoon SE, et al
    Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
    J Neuroimmunol. 2021;355:577564.
    PubMed     Abstract available


  125. GOVIL-DALELA T, Datta I, Williams M
    Refractory NMDA-receptor encephalitis in a teenager: A novel use of Bortezomib.
    J Neuroimmunol. 2021;355:577565.
    PubMed     Abstract available


  126. SON H, Lee WJ, Moon J, Yoon S, et al
    Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    J Neuroimmunol. 2021;355:577551.
    PubMed     Abstract available


  127. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available


  128. FINSTERER J, Ghosh R
    Dimensions of SARS-CoV-2 associated Guillain-Barre syndrome.
    J Neuroimmunol. 2021;357:577626.
    PubMed    


  129. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available


    May 2021
  130. GRISANTI SG, Franciotta D, Garnero M, Zuppa A, et al
    A case series of parainfectious Guillain-Barre syndrome linked to influenza A (H1N1) virus infection.
    J Neuroimmunol. 2021;357:577605.
    PubMed     Abstract available


  131. MANOUCHEHRI N, Guisso DR, Hussain RZ, Minassian BA, et al
    The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo.
    J Neuroimmunol. 2021;354:577544.
    PubMed     Abstract available


  132. WANG T, Wang B, Zeng Z, Li H, et al
    Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.
    J Neuroimmunol. 2021;354:577527.
    PubMed     Abstract available


  133. FINSTERER J, Scorza FA, Scorza CA, Fiorini AC, et al
    Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.
    J Neuroimmunol. 2021;357:577609.
    PubMed    


  134. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available


  135. ROTOLO RA, Demuro J, Drummond G, Little C, et al
    Prophylactic exposure to oral riluzole reduces the clinical severity and immune-related biomarkers of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577603.
    PubMed     Abstract available


  136. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available


  137. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available


  138. ZULIANI L, Marangoni S, De Gaspari P, Rosellini I, et al
    Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics.
    J Neuroimmunol. 2021 May 1:577598. doi: 10.1016/j.jneuroim.2021.577598.
    PubMed     Abstract available


    April 2021
  139. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.
    PubMed    


  140. DOPPLER K, Hemprich A, Haarmann A, Brecht I, et al
    Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis.
    J Neuroimmunol. 2021;356:577588.
    PubMed     Abstract available


  141. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available


  142. MASI G, Spagni G, Campetella L, Monte G, et al
    Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis.
    J Neuroimmunol. 2021;356:577601.
    PubMed     Abstract available


  143. PAPRI N, Hayat S, Mohammed A, Afsar MNA, et al
    Guillain-Barre syndrome associated with SARS-CoV-2 infection: A case report with long term follow up.
    J Neuroimmunol. 2021;356:577590.
    PubMed     Abstract available


  144. HOU H, Sun Y, Miao J, Gao M, et al
    Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577583.
    PubMed     Abstract available


  145. SHEIKH AB, Chourasia PK, Javed N, Chourasia MK, et al
    Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review.
    J Neuroimmunol. 2021;355:577577.
    PubMed     Abstract available


  146. MORENO-ESCOBAR MC, Kataria S, Khan E, Subedi R, et al
    Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature.
    J Neuroimmunol. 2021;353:577523.
    PubMed     Abstract available


  147. JUMAH M, Rahman F, Figgie M, Prasad A, et al
    COVID-19, HHV6 and MOG antibody: A perfect storm.
    J Neuroimmunol. 2021;353:577521.
    PubMed     Abstract available


  148. WANG J, Qiu Z, Li D, Dong H, et al
    Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.
    J Neuroimmunol. 2021;353:577515.
    PubMed     Abstract available


  149. ZHANG H, Yang Y, Luo X
    Anti-MOG antibodies associated demyelination following encephalomeningitis: Case report.
    J Neuroimmunol. 2021;353:577519.
    PubMed     Abstract available


  150. LI C, Wang J, Sun X, Li R, et al
    The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.
    J Neuroimmunol. 2021;353:577506.
    PubMed     Abstract available


  151. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available


  152. FANG F, Wang Y, Xu W
    Anti-N-methyl-d-aspartate receptor encephalitis associated with intracranial cryptococcal infection: A case report and 2-year follow-up.
    J Neuroimmunol. 2021;353:577502.
    PubMed     Abstract available


  153. DU Q, Shi Z, Chen H, Zhang Y, et al
    Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2021;353:577494.
    PubMed     Abstract available


  154. PRADO MB JR, Narito KM, Adiao KJB
    Anti-GM1 IgM antibody positive axonal variant of Guillain-Barre-syndrome in a pediatric patient with dengue fever.
    J Neuroimmunol. 2021;355:577572.
    PubMed     Abstract available


  155. FAN Z, Zheng D, Wen X, Shen F, et al
    CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
    J Neuroimmunol. 2021;355:577571.
    PubMed     Abstract available


  156. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available


    March 2021
  157. GUEDES BF, Ribeiro AF, Pinto LF, Vidal JE, et al
    Potential autoimmune encephalitis following yellow fever vaccination: A report of three cases.
    J Neuroimmunol. 2021;355:577548.
    PubMed     Abstract available


  158. LAZAREVIC M, Djedovic N, Stanisavljevic S, Dimitrijevic M, et al
    Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies.
    J Neuroimmunol. 2021;354:577547.
    PubMed     Abstract available


  159. DINOTO A, Bosco A, Sartori A, Bratina A, et al
    Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies.
    J Neuroimmunol. 2021;352:577488.
    PubMed     Abstract available


  160. LI X, Hou C, Wu WL, Liang H, et al
    Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: Analysis of 111 cases.
    J Neuroimmunol. 2021;352:577479.
    PubMed     Abstract available


  161. DAY GS, Gordon BA, Bucelli RC, Perrin RJ, et al
    Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient.
    J Neuroimmunol. 2021;352:577474.
    PubMed     Abstract available


  162. COSSU D, Yokoyama K, Sakanishi T, Kuwahara-Arai K, et al
    A mucosal immune response induced by oral administration of heat-killed Mycobacterium avium subsp. paratuberculosis exacerbates EAE.
    J Neuroimmunol. 2021;352:577477.
    PubMed     Abstract available


  163. CHAUDHARY P, Marracci GH, Calkins E, Pocius E, et al
    Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.
    J Neuroimmunol. 2021;352:577468.
    PubMed     Abstract available


  164. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
    Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    J Neuroimmunol. 2021;354:577541.
    PubMed     Abstract available


    February 2021
  165. XIANG W, Xie C, Guan Y
    The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis.
    J Neuroimmunol. 2021;354:577520.
    PubMed     Abstract available


  166. LI H, Huang Z, Jia D, Xue H, et al
    Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    J Neuroimmunol. 2021;354:577528.
    PubMed     Abstract available


  167. LUCCHINI M, Giuffre GM, Nociti V, Bianco A, et al
    Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis.
    J Neuroimmunol. 2021;353:577525.
    PubMed     Abstract available


  168. AKAISHI T, Misu T, Takahashi T, Takai Y, et al
    Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
    J Neuroimmunol. 2021;351:577467.
    PubMed     Abstract available


  169. CHOUDHARY A, Bhargava A, Khichar S, Pradhan S, et al
    Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India.
    J Neuroimmunol. 2021;351:577456.
    PubMed     Abstract available


  170. THIRUNAVUKKARASU B, Gupta K, Nada R, Rathi M, et al
    Neuropathological spectrum in systemic lupus erythematosus: A single institute autopsy experience.
    J Neuroimmunol. 2021;353:577518.
    PubMed     Abstract available


  171. UCHIDA N, Mori K, Fujita-Nakata M, Nakanishi M, et al
    Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
    J Neuroimmunol. 2021;353:577500.
    PubMed     Abstract available


  172. LI Q, Liu Y, Zeng Y
    Questions about data: Importance of serum amyloid A level in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577516.
    PubMed    


    January 2021
  173. YUE YX, Gao X, Tang TP, Xie Y, et al
    Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.
    J Neuroimmunol. 2021;353:577487.
    PubMed     Abstract available


  174. BEER R, Lehn A, Blum S
    A case of Anti-LGi-1 antibody positive autoimmune epilepsy following deep brain stimulator implantation for essential tremor.
    J Neuroimmunol. 2021;353:577503.
    PubMed     Abstract available


  175. NING P, Yang B, Yang X, Huang H, et al
    Lymphocyte-based ratios for predicting respiratory failure in Guillain-Barre syndrome.
    J Neuroimmunol. 2021;353:577504.
    PubMed     Abstract available


  176. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
    An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577507.
    PubMed     Abstract available


  177. BROADLEY J, Wesselingh R, Seneviratne U, Kyndt C, et al
    Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis.
    J Neuroimmunol. 2021;353:577508.
    PubMed     Abstract available


  178. MIMPEN M, Rolf L, Muris AH, Gerlach O, et al
    NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.
    J Neuroimmunol. 2021;353:577499.
    PubMed     Abstract available


  179. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
    Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577497.
    PubMed     Abstract available


  180. NIU Y, Li Y
    The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.
    J Neuroimmunol. 2021;352:577465.
    PubMed    


  181. MORIGUCHI K, Miyamoto K, Fukumoto Y, Kusunoki S, et al
    Change in light-dark cycle affects experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;353:577495.
    PubMed     Abstract available


  182. CHU Y, Jing Y, Zhao X, Wang M, et al
    Modulation of the HMGB1/TLR4/NF-kappaB signaling pathway in the CNS by matrine in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;352:577480.
    PubMed     Abstract available


  183. ZILIOTTO N, Lamberti N, Manfredini F, Straudi S, et al
    Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
    J Neuroimmunol. 2021;352:577473.
    PubMed     Abstract available


    December 2020
  184. KOHLE F, Sprenger A, Klein I, Fink GR, et al
    Nerve conductions studies in experimental models of autoimmune neuritis: A meta-analysis and guideline.
    J Neuroimmunol. 2020;352:577470.
    PubMed     Abstract available


  185. STASCHEIT F, Li L, Mai K, Baum K, et al
    Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.
    J Neuroimmunol. 2020;351:577469.
    PubMed     Abstract available


  186. YOKOTE H, Toru S, Nishida Y, Hattori T, et al
    Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.
    J Neuroimmunol. 2020;351:577466.
    PubMed     Abstract available


  187. AKAISHI T, Fujimori J, Takahashi T, Misu T, et al
    Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.
    J Neuroimmunol. 2020;349:577431.
    PubMed     Abstract available


  188. UZAWA A, Ozawa Y, Yasuda M, Kuwabara S, et al
    Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
    J Neuroimmunol. 2020;349:577424.
    PubMed     Abstract available


  189. GARCIA-FERNANDEZ FJ, Garcia-Fernandez AE, Nava E, Del Pozo JSG, et al
    A bibliometric evaluation of the top 100 cited natalizumab articles.
    J Neuroimmunol. 2020;349:577379.
    PubMed     Abstract available


  190. HUSSEIN O, Abd Elazim A, Torbey MT
    Covid-19 systemic infection exacerbates pre-existing acute disseminated encephalomyelitis (ADEM).
    J Neuroimmunol. 2020;349:577405.
    PubMed     Abstract available


  191. ZHENG Y, Luo J, Jin H, Gao F, et al
    Cerebrospinal fluid CD20 positive B-cell expansion in a case of anti-NMDAR encephalitis.
    J Neuroimmunol. 2020;349:577365.
    PubMed     Abstract available


    November 2020
  192. MOUTRAN-BARROSO H, Kreinter-Rosembaun H, Beltran S MA, Bayona H, et al
    The multiple faces of encephalitis: Antibody profile in a case series of autoimmune encephalitis in Bogota, Colombia.
    J Neuroimmunol. 2020;350:577451.
    PubMed     Abstract available


  193. MA X, Kermode AG, Hu X, Qiu W, et al
    NMOSD acute attack: Understanding, treatment and innovative treatment prospect.
    J Neuroimmunol. 2020;348:577387.
    PubMed     Abstract available


  194. GHOSH R, Dubey S, Ray BK, Purkait S, et al
    Isolated opsoclonus heralding neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2020;348:577394.
    PubMed     Abstract available


  195. XING X, Li J, Chen S, Zheng L, et al
    Anti-CASPR2 antibody associated encephalitis with anosmia and demyelinating pseudotumor: A case report.
    J Neuroimmunol. 2020;348:577393.
    PubMed     Abstract available


  196. KWON YN, Kim B, Ahn S, Seo J, et al
    Serum level of IL-1beta in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
    J Neuroimmunol. 2020;348:577361.
    PubMed     Abstract available


  197. GUO J, Han B, Wang J, Zhang L, et al
    The differential expression and potential roles of circular RNAs in children with anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2020;348:577381.
    PubMed     Abstract available


  198. BILGE N, Simsek F, Yevgi R, Ceylan M, et al
    Low serum Alpha-SYNUCLEIN and oligomer Alpha-SYNUCLEIN levels in multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577432.
    PubMed     Abstract available


  199. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577433.
    PubMed     Abstract available


  200. GONCALVES MVM, Brandao WN, Longo C, Peron JPS, et al
    Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
    J Neuroimmunol. 2020;350:577435.
    PubMed     Abstract available


    October 2020
  201. SUN H, Wang J, Guo L, Wang Y, et al
    The combined treatment of NAD(+) and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.
    J Neuroimmunol. 2020;350:577429.
    PubMed     Abstract available


  202. MARTINEZ-LARROSA J, Matute-Blanch C, Montalban X, Comabella M, et al
    Modelling multiple sclerosis using induced pluripotent stem cells.
    J Neuroimmunol. 2020;349:577425.
    PubMed     Abstract available


  203. JEBALI A, Noroozi Karimabad M, Ahmadi Z, Khorramdel H, et al
    Attenuation of inflammatory response in the EAE model by PEGlated nanoliposome of pistachio oils.
    J Neuroimmunol. 2020;347:577352.
    PubMed     Abstract available


  204. QIU Y, Zhou Q, Du Q, Chen H, et al
    Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China.
    J Neuroimmunol. 2020;347:577351.
    PubMed    


  205. DUBEY S, Ghosh R, Dubey MJ, Sengupta S, et al
    Bilateral thalamic changes in anti-NMDAR encephalitis presenting with hemichorea and dystonia and acute transient psychotic disorder.
    J Neuroimmunol. 2020;347:577329.
    PubMed     Abstract available


  206. LI HX, Zuo L, Peng XX, Zong Q, et al
    Immunoglobulin G4-related hypertrophic pachymeningitis with spinal cord compression: A case report.
    J Neuroimmunol. 2020;347:577325.
    PubMed     Abstract available


    September 2020
  207. MATTEO G, Massimiliano T, Giorgia C, Silvia S, et al
    AQP4 autoantibodies in patients with idiopathic normal pressure hydrocephalus.
    J Neuroimmunol. 2020;349:577407.
    PubMed     Abstract available


  208. NEKRASOVA I, Shirshev S
    Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
    J Neuroimmunol. 2020;349:577421.
    PubMed     Abstract available


  209. HAWKE S, Zinger A, Juillard PG, Holdaway K, et al
    Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    J Neuroimmunol. 2020;349:577392.
    PubMed     Abstract available


  210. YAN C, Zhao R, Song J, Feng X, et al
    Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
    J Neuroimmunol. 2020;349:577403.
    PubMed     Abstract available


  211. YAMAKAWA M, Mukaino A, Kimura A, Nagasako Y, et al
    Antibodies to the alpha3 subunit of the ganglionic-type nicotinic acetylcholine receptors in patients with autoimmune encephalitis.
    J Neuroimmunol. 2020;349:577399.
    PubMed     Abstract available


  212. YILMAZ V, Tuzun E, Durmus H, Oflazer P, et al
    The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients.
    J Neuroimmunol. 2020;349:577402.
    PubMed     Abstract available


  213. HOWLETT-PRIETO Q, Langer C, Rezania K, Soliven B, et al
    Modulation of immune responses by bile acid receptor agonists in myasthenia gravis.
    J Neuroimmunol. 2020;349:577397.
    PubMed     Abstract available


  214. ZHONG H, Lu J, Jing S, Xi J, et al
    Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
    J Neuroimmunol. 2020;348:577383.
    PubMed     Abstract available


  215. PARKHOUSE RME, Sciutto E, Hernandez M, Cortez MM, et al
    Extraparenchymal human neurocysticercosis induces autoantibodies against brain tubulin and MOG35-55 in cerebral spinal fluid.
    J Neuroimmunol. 2020;349:577389.
    PubMed     Abstract available


  216. DAS A, Khurshid S, Hayat S, Ahmed R, et al
    Glucocorticoid receptor gene polymorphisms in Guillain-Barre syndrome.
    J Neuroimmunol. 2020;348:577388.
    PubMed     Abstract available


  217. SIGNORIELLO E, Iardino P, Casertano S, De Lucia D, et al
    12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
    J Neuroimmunol. 2020;348:577385.
    PubMed     Abstract available


  218. ZOUVELOU V, Psimenou E
    AChR-and MuSK-positive myasthenia gravis: Double trouble.
    J Neuroimmunol. 2020;348:577364.
    PubMed     Abstract available


    August 2020
  219. ZHAN L, Fan M, Cai N, Cai B, et al
    Combination of autoimmune pancreatitis and peripheral neuropathy on an IgG4-related disease patient with 4 years following-up.
    J Neuroimmunol. 2020;348:577378.
    PubMed     Abstract available


  220. HEBERT J, Gros P, Lapointe S, Amtashar FS, et al
    Searching for autoimmune encephalitis: Beware of normal CSF.
    J Neuroimmunol. 2020;345:577285.
    PubMed     Abstract available


  221. LI X, Gao Q, Yang L, Han M, et al
    Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells.
    J Neuroimmunol. 2020;345:577286.
    PubMed     Abstract available


  222. JIAO L, Xiang Y, Li S, Zhang F, et al
    Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155.
    J Neuroimmunol. 2020;345:577280.
    PubMed     Abstract available


  223. ISMAIL S, Engin K, Ozan K, Mustafa C, et al
    Analysis of plasma protein biomarkers in childhood onset multiple sclerosis.
    J Neuroimmunol. 2020;348:577359.
    PubMed     Abstract available


  224. TRENOVA AG, Miteva LD, Stanilova SA
    Association between TNFA, IL10 and IL18 promoter gene variants and cognitive functions in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2020;347:577357.
    PubMed     Abstract available


  225. SOTIROPOULOS MG, Chitnis T
    Opposing and potentially antagonistic effects of BMP and TGF-beta in multiple sclerosis: The "Yin and Yang" of neuro-immune Signaling.
    J Neuroimmunol. 2020;347:577358.
    PubMed     Abstract available


  226. IBRAHIM SH, El-Mehdawy KM, Seleem M, El-Sawalhi MM, et al
    Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
    J Neuroimmunol. 2020;347:577356.
    PubMed     Abstract available


  227. SALAVISA M, Paixao P, Ladeira AF, Mendes A, et al
    Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse.
    J Neuroimmunol. 2020;347:577355.
    PubMed     Abstract available


    July 2020
  228. GARG D, Agarwal A, Bhagyawant R, Sikand TS, et al
    De novo nose-pinching stereotypy with somnolence: Clues to autoimmune encephalitis.
    J Neuroimmunol. 2020;347:577348.
    PubMed     Abstract available


  229. ACAR NP, Tuncer A, Ozkazanc D, Ozbay FG, et al
    An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta1 and fingolimod therapy.
    J Neuroimmunol. 2020;347:577353.
    PubMed     Abstract available


  230. GHADERIAN S, Shomali N, Behravesh S, Danbaran GR, et al
    The emerging role of lncRNAs in multiple sclerosis.
    J Neuroimmunol. 2020;347:577347.
    PubMed     Abstract available


  231. STEFANOVIC M, Zivotic I, Stojkovic L, Dincic E, et al
    The association of genetic variants IL2RA rs2104286, IFI30 rs11554159 and IKZF3 rs12946510 with multiple sclerosis onset and severity in patients from Serbia.
    J Neuroimmunol. 2020;347:577346.
    PubMed     Abstract available


  232. CULLER G, Bachman E, VanHaerents S
    Paraclinical serum markers as aids in the diagnosis of autoimmune encephalitis.
    J Neuroimmunol. 2020;347:577324.
    PubMed     Abstract available


  233. CIARDI MR, Zingaropoli MA, Pasculli P, Perri V, et al
    The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia.
    J Neuroimmunol. 2020;346:577323.
    PubMed     Abstract available


  234. KENNEDY PGE, Graner MW, Walker D, Pointon T, et al
    Recombinant antibodies derived from laser captured single plasma cells of multiple sclerosis brain identified phage peptides which may be used as tools for characterizing intrathecal IgG response.
    J Neuroimmunol. 2020;347:577319.
    PubMed     Abstract available


  235. TIAN X, Chen C, Ma L, Wei R, et al
    Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2020;347:577317.
    PubMed     Abstract available


  236. HOUEN G, Heiden J, Trier NH, Draborg AH, et al
    Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis.
    J Neuroimmunol. 2020;346:577314.
    PubMed     Abstract available


  237. KEYVANI H, Zahednasab H, Aljanabi HAA, Asadi M, et al
    The role of human herpesvirus-6 and inflammatory markers in the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2020;346:577313.
    PubMed     Abstract available


    June 2020
  238. YETKIN MF, Mirza M
    Neutrophil to-lymphocyte ratio as a possible predictor of prognosis in recently diagnosed multiple sclerosis patients.
    J Neuroimmunol. 2020;346:577307.
    PubMed    


  239. FARAHMAND F, Nourshahi M, Soleimani M, Rajabi H, et al
    The effect of 6 weeks of high intensity interval training on myelin biomarkers and demyelination in experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2020;346:577306.
    PubMed     Abstract available


  240. FARZI MA, Ayromlou H, Jahanbakhsh N, Bavil PH, et al
    Guillain-Barre syndrome in a patient infected with SARS-CoV-2, a case report.
    J Neuroimmunol. 2020;346:577294.
    PubMed     Abstract available


  241. AL-NASERI MAS, Salman ED, Ad'hiah AH
    Relapsing-remitting multiple sclerosis: A profile of interleukine-1 gene cluster polymorphisms in Iraqi patients.
    J Neuroimmunol. 2020;346:577291.
    PubMed     Abstract available


  242. RYBERG B, Arvidsson A, Bergkvist M, Nilsson P, et al
    Limbic encephalitis in a neuroscientist: CASPR 2 antibody-associated disease after antigen exposure.
    J Neuroimmunol. 2020;343:577231.
    PubMed     Abstract available


  243. JUNG KO, Moon HJ
    A case of NMDAR encephalitis treated in the third trimester - novel arterial spin labeling findings and a review of literature.
    J Neuroimmunol. 2020;343:577235.
    PubMed     Abstract available


  244. AKAISHI T, Takahashi T, Fujihara K, Misu T, et al
    Risk factors of attacks in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;343:577236.
    PubMed     Abstract available


  245. GONZALEZ-ALVARADO MN, Rotger C, Berger L, London B, et al
    Functional role of endogenous Kv1.4 in experimental demyelination.
    J Neuroimmunol. 2020;343:577227.
    PubMed     Abstract available


  246. NAJJAR E, Staun-Ram E, Volkowich A, Miller A, et al
    Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    J Neuroimmunol. 2020;343:577230.
    PubMed     Abstract available


  247. SUN H, Ma X, Sun X, Wu L, et al
    Is transient hyperCKemia a new feature of neuromyelitis optica spectrum disorders? A retrospective study in 439 patients.
    J Neuroimmunol. 2020;343:577228.
    PubMed     Abstract available


  248. AHARONI R, Eilam R, Schottlender N, Radomir L, et al
    Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis.
    J Neuroimmunol. 2020;345:577281.
    PubMed     Abstract available


    May 2020
  249. RACKE MK, Newsome SD
    Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
    J Neuroimmunol. 2020 May 31:577283. doi: 10.1016/j.jneuroim.2020.577283.
    PubMed    


  250. CHIARINI M, Paghera S, Moratto D, Rossi N, et al
    Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
    J Neuroimmunol. 2020;345:577282.
    PubMed     Abstract available


  251. LI Y, Guptill JT, Russo MA, Howard JF Jr, et al
    Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis.
    J Neuroimmunol. 2020;345:577279.
    PubMed     Abstract available


  252. GRIFFITH SP, Malpas CB, Alpitsis R, O'Brien TJ, et al
    The neuropsychological spectrum of anti-LGI1 antibody mediated autoimmune encephalitis.
    J Neuroimmunol. 2020;345:577271.
    PubMed     Abstract available


  253. MAURICE C, Khoja L, Morgan E, Mason WP, et al
    Guillain-Barre Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming.
    J Neuroimmunol. 2020;346:577267.
    PubMed     Abstract available


  254. KAPADIA RK, Ney DE, Hannan M, Farley M, et al
    Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
    J Neuroimmunol. 2020;344:577259.
    PubMed     Abstract available


    April 2020
  255. KEFALOPOULOU ZM, Liossis SN, Sagona T, Veltsista D, et al
    An ischemic stroke as the presenting manifestation of rapidly progressive primary angiitis of central nervous system in a 17-year-old boy.
    J Neuroimmunol. 2020;341:577190.
    PubMed     Abstract available


  256. LI X, Guo Q, Zheng Z, Wang X, et al
    Immune-mediated epilepsy with GAD65 antibodies.
    J Neuroimmunol. 2020;341:577189.
    PubMed     Abstract available


  257. BERNARDO F, Rebordao L, Rego A, Machado S, et al
    Stiff person spectrum disorders: An illustrative case series of their phenotypic and antibody diversity.
    J Neuroimmunol. 2020;341:577192.
    PubMed     Abstract available


  258. SHIBUYA K, Tsuneyama A, Misawa S, Sekiguchi Y, et al
    Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes.
    J Neuroimmunol. 2020;341:577170.
    PubMed     Abstract available


  259. PREVEZIANOU A, Tzartos JS, Dagklis IE, Bentenidi E, et al
    Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
    J Neuroimmunol. 2020;344:577242.
    PubMed     Abstract available


  260. ANEJA J, Kuppili PP, Paul K, Panda S, et al
    Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male.
    J Neuroimmunol. 2020;343:577238.
    PubMed     Abstract available


  261. BOULLERNE AI, Adami GR, Schwartz JL, Skias D, et al
    Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity.
    J Neuroimmunol. 2020;343:577237.
    PubMed     Abstract available


  262. PARKHOUSE RME, Carpio A, Cortez MM, von Kriegsheim A, et al
    Anti-brain protein autoantibodies are detectable in extraparenchymal but not parenchymal neurocysticercosis.
    J Neuroimmunol. 2020;344:577234.
    PubMed     Abstract available


    March 2020
  263. PRABHAT N, Chakravarty K, Pattnaik SN, Takkar A, et al
    Systemic lupus erythematosus with autoimmune neurological manifestations in a carrier of chronic granulomatous disease - a rare presentation.
    J Neuroimmunol. 2020;343:577229.
    PubMed     Abstract available


  264. MUKE I, Sprenger A, Bobylev I, Wiemer V, et al
    Ultrastructural characterization of mitochondrial damage in experimental autoimmune neuritis.
    J Neuroimmunol. 2020;343:577218.
    PubMed     Abstract available


  265. BOLDRINI VO, Brandao CO, Pimentel MLV, Vidal A, et al
    Massive activity of cytotoxic cells during refractory Neuromyelitis Optica spectrum disorder.
    J Neuroimmunol. 2020;340:577148.
    PubMed     Abstract available


  266. AKAISHI T, Takahashi T, Himori N, Fujihara K, et al
    Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;340:577168.
    PubMed     Abstract available


  267. URIBE-SAN-MARTIN R, Ciampi E, Cruz JP, Vasquez M, et al
    Refractory epilepsy associated with anti-ribosomal P antibodies successfully treated with topiramate.
    J Neuroimmunol. 2020;340:577144.
    PubMed     Abstract available


  268. MADDISON P, Gozzard P, Sadalage G, Ambrose PA, et al
    Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.
    J Neuroimmunol. 2020;340:577149.
    PubMed     Abstract available


  269. PEDAPATI R, Bhatia R, Singh N, Bali P, et al
    Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum - A north Indian tertiary care centre experience and review of literature.
    J Neuroimmunol. 2020;340:577143.
    PubMed     Abstract available


    February 2020
  270. OGATA H, Isobe N, Zhang X, Yamasaki R, et al
    Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2020;339:577139.
    PubMed     Abstract available


  271. SHI Z, Qiu Y, Wang J, Fang Y, et al
    Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study.
    J Neuroimmunol. 2020;339:577126.
    PubMed     Abstract available


  272. BRILL L, Vaknin-Dembinsky A, Zveik O, Haham N, et al
    MIF -173G/C polymorphism is associated with NMO disease severity.
    J Neuroimmunol. 2020;339:577120.
    PubMed     Abstract available


  273. GARIMELLA V, McVoy JS, Oh U
    The contribution of cyclophilin A to immune-mediated central nervous system inflammation.
    J Neuroimmunol. 2020;339:577118.
    PubMed     Abstract available


  274. ZHANG W, Dong M, Dong H, Wang W, et al
    Reduced sarcolemmal aquaporin 4 expression can support the differential diagnosis of neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2020;339:577121.
    PubMed     Abstract available


  275. GOMES NA, Silva PC, Teixeira YT, Eufrazio P, et al
    HLA-G Ins/Del polymorphism and +3142C/G SNP are not related to neuromyelitis optica spectrum disorder (NMOSD) development, disability status or anti-aquaporin 4 presence in Brazilian patients.
    J Neuroimmunol. 2020;339:577112.
    PubMed     Abstract available


  276. NYSTAD AE, Lereim RR, Wergeland S, Oveland E, et al
    Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
    J Neuroimmunol. 2020;339:577091.
    PubMed     Abstract available


    January 2020
  277. ZHANG Y, Zhang Q, Shi Z, Chen H, et al
    Sexual dysfunction in patients with neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2020;338:577093.
    PubMed     Abstract available


  278. AGASING AM, Gawde S, Kumar G, Turner E, et al
    B cell function impacts the efficacy of IFN-beta therapy in EAE.
    J Neuroimmunol. 2020;338:577106.
    PubMed     Abstract available


  279. BLACKBURN K, Wang C, Greenberg B
    Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma.
    J Neuroimmunol. 2020;338:577092.
    PubMed     Abstract available


    July 2019
  280. NICOLETTI F, Mazzon E, Fagone P, Mangano K, et al
    Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF.
    J Neuroimmunol. 2019;332:224-232.
    PubMed     Abstract available


  281. DZANGUE-TCHOUPOU G, Allenbach Y, Preusse C, Stenzel W, et al
    Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome.
    J Neuroimmunol. 2019;332:212-215.
    PubMed     Abstract available


  282. JAZEBI N, Rodrigo S, Gogia B, Shawagfeh A, et al
    Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
    J Neuroimmunol. 2019;332:135-137.
    PubMed     Abstract available


  283. ENRIQUEZ CAG, Espiritu AI, Pasco PMD
    Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
    J Neuroimmunol. 2019;332:126-134.
    PubMed     Abstract available


  284. NEEDHAM EJ, Helmy A, Zanier ER, Jones JL, et al
    The immunological response to traumatic brain injury.
    J Neuroimmunol. 2019;332:112-125.
    PubMed     Abstract available


  285. FREUND B, Ritzl EK
    A review of EEG in anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2019;332:64-68.
    PubMed     Abstract available


  286. CAVALIERE E, Nosadini M, Pelizza MF, Ventura G, et al
    Anti-NMDAR encephalitis preceded by non-herpetic central nervous system infection: Systematic literature review and first case of tick-borne encephalitis triggering anti-NMDAR encephalitis.
    J Neuroimmunol. 2019;332:1-7.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: